Peter DeMuth

Company: Elicio Therapeutics

Job title: Chief Scientific Officer

Seminars:

Levelling Up Cancer Vaccines With TLR Agonist Adjuvants 1:00 pm

Highlighting the potential of TLR agonists in enhancing the efficacy of a range of vaccines Taking away valuable insights from the COVID-19 vaccines and adapting this to enhance cancer vaccines Improving the immunogenicity of an encoded transgene in the vaccineRead more

day: Conference Day Two

Panel Discussion: Weighing Up Innate Immune Activation vs Suppression & What We Can Take Away From Understanding Antagonists 3:30 pm

Facilitating a discussion between agonist and antagonist drug developers is key to gaining a better insight into the overall functioning of STING and TLR pathways. This panel discussion will span across both sides of this reflecting on: The perspective of antagonist developers on what drives autoimmune overactivation and exploring if this can be replicated selectively…Read more

day: Conference Day Two